Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56856 | 0.98 | EPHX1 (0.53) | EPHX1BTKCTSKPOLBGAA | |
| Water SCHEMBL27795194 | 0.96 | EPHX1 (0.52) | EPHX1BTKCTSKPOLBGAA | |
| Hydrochloric Acid SCHEMBL4158527 | 0.96 | EPHX1 (0.52) | EPHX1BTKCTSKPOLBGAA | |
| Alcohol SCHEMBL28064671 | 0.92 | BTK (0.48) | EPHX1BTKCTSKPOLBGAA | |
| SCHEMBL14209088 | 0.92 | BTK (0.55) | EPHX1BTKCTSKPOLBGAA | |
| SCHEMBL555051 | 0.92 | BTK (0.55) | EPHX1BTKCTSKPOLBGAA | |
| Acetic Acid Methyl Ester SCHEMBL8483324 | 0.92 | BTK (0.48) | EPHX1BTKCTSKPOLBGAA | |
| Formic Acid SCHEMBL7216484 | 0.92 | BTK (0.48) | EPHX1BTKCTSKPOLBGAA | |
| SCHEMBL14209134 | 0.92 | BTK (0.55) | EPHX1BTKCTSKPOLBGAA | |
| Methyl Carbamate SCHEMBL28171804 | 0.90 | BTK (0.47) | EPHX1BTKCTSKPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108135897-B | Fused benzamides | 勃林格殷格翰国际有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3337483-B1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2019-10-09 | — | — | EP | disclosed |
| US-20180186774-A1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2018-07-05 | — | — | US | disclosed |
| EP-3337483-A1 | NOVEL ANNELATED BENZAMIDES | Boehringer Ingelheim International GmbH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-2794595-B1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| WO-2017028926-A1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-23 | — | — | WO | disclosed |
| EP-2794595-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8859559-B2 | Substituted pyrazines and their use in the treatment of disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| WO-2013092674-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157981-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | EPHX1 2356/4885BTK 2427/4885CTSK 2256/4885 |
| US-20180186774-A1 | NOVEL ANNELATED BENZAMIDES | HDAC10, HDAC11, H1-0 | EPHX1 3124/4885BTK 470/4885CTSK 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.